Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury

V A J Maria, R M M Victorino

Abstract

Background—Diagnosis of drug induced liver injury is usually based on a temporal relation between drug intake and clinical picture as well as on the exclusion of alternative causes. More precise diagnosis has been attempted by using in vitro specific T cell reactivity to drugs but the test has never reached general acceptability because of frequent negative results which could be explained, in part, by prostaglandin producing suppressor cells (PPSC).

Aim—To analyse the diagnostic value of a modified test where lymphocyte responses to drugs are detected in the presence of a prostaglandin inhibitor.

Patients—Ninety five patients with a clinical diagnosis of drug induced liver injury, 106 healthy controls, 35 individuals with recent exposure to the same drugs without adverse effects, and 15 patients with liver disease unrelated to drugs.

Methods—Peripheral blood mononuclear cells (PBMC) were cultured in the presence of drugs alone and in the presence of drugs and a prostaglandin inhibitor. Responses were assessed by ³H-thymidine incorporation in lymphocytes. Results were expressed as counts per minute and as stimulation indexes (SI).

Results—When PBMC were stimulated with drugs alone, lymphocyte sensitisation to drugs (SI>2) was detected in 26% of the cases. This was noticeably increased (56%) when a prostaglandin inhibitor was added to the cultures. No reactivity was found in controls. In patients with possible sensitivity to several drugs, lymphocyte reactivity was detected to only one drug. The severity of the lesions, as assessed by aminotransferase concentrations and disease duration, was lower in patients with evidence of PPSC.

Conclusions—This new approach is useful for the diagnosis of drug induced liver injury, particularly in patients exposed to more than one drug; furthermore, the presence of putative PPSC is associated with less severe forms of drug induced hepatitis.

(Gut 1997; 41: 534-540)

Keywords: drug induced hepatitis; drug hypersensitivity; specific T cells; prostaglandin E₂; suppressor cells; diagnostic tests

dose independent idiosyncratic mechanisms.¹ Diagnosis of drug induced liver injury in the rare cases of dose dependent reactions is straightforward, whereas diagnosis of the more common dose independent adverse reactions relies on clinical criteria that are sometimes difficult to apply, particularly in patients exposed to more than one drug.^{2,3} Two different dose independent mechanisms may be involved in drug induced liver injury: allergic hypersensitivity, and metabolic idiosyncrasy associated with the accumulation of reactive metabolites. These can damage hepatic structures by direct mechanisms^{4,5} or can covalently bind to macromolecules (membrane or plasma proteins) and form an antigen, which in turn, elicits a hypersensitivity reaction.^{4,6} It has been suggested that in most cases of drug induced liver injury, even when metabolic idiosyncrasy is the initiating feature, immunological hypersensitivity can be involved as an effector mechanism.^{4,7}

The most convincing evidence in favour of an allergic basis for the drug induced liver disorder is the demonstration of specific antibodies⁸ or sensitised T cells to the drug or its metabolites.⁹⁻¹³ Unfortunately, immunological tests are rarely performed in cases of suspected drug induced liver injury and in many published studies they are reported as negative.^{14,15} This could be a consequence of inadequate antigenic presentation of the drug or, alternatively, could be due to the presence of putative suppressor factors in the in vitro culture systems. We have presented evidence previously that several modifications to the test—namely, the addition of a prostaglandin inhibitor to the culture system^{16,17} and the use of ex vivo prepared drug antigens or metabolites instead of the parental drug,^{9,18} may improve detection of lymphocyte sensitisation to drugs in cases of drug induced hepatitis.

The list of drugs involved in liver injury continues to increase although it is usually accepted that no significant improvement in the accuracy of the diagnosis has occurred.^{3,19} In view of the new methods for studying in vitro sensitisation to drugs,^{16,18} it is important to assess the diagnostic value of such modified immunological tests in a large series of patients. In this study we present results of the in vitro lymphocyte reactivity to drugs in the presence of a prostaglandin inhibitor, tested in a series of 95 patients with a clinical diagnosis of drug induced liver injury, in order to clarify the diagnostic impact of this approach.

University Hospital of Santa Maria,
Department of Medicine 2/Clinical Immunology, Av. Prof. Egas Moniz, 1600 Lisbon, Portugal
V A J Maria
R M M Victorino

Correspondence to:
Dr V A J Maria.

Accepted for publication
25 March 1997

Drug induced liver injury can occur as a result of dose dependent, intrinsic drug toxicity or by

TABLE 1 Clinical characteristics of the patients studied

Number of patients	95
Age (mean (SD))	45.1 (18.6)
Sex (M/F)	40/55
Drugs taken	
Mean (SEM)	3.9 (0.2)
Limits	1–12
Drugs tested	
Mean (SEM)	1.6 (0.1)
Limits	1–6
Latency time*	
Median (days)	15
Limits	3 days to 2 years
Rechallenge (intentional or accidental)	11
Remission time†	
Median (days)	58
Limits	14 days to 2.5 years

*Time from beginning of drug intake to the onset of symptoms.

†Time from withdrawal of the drug until normalisation of liver function tests.

Methods

PATIENTS AND CONTROLS

Ninety five patients with a final clinical diagnosis of drug induced liver injury were investigated (table 1). They were consecutively referred to our unit for clinical opinion and immunological studies, between 1985 and 1996. Forty two of these patients were included in the initial study describing prostaglandin producing suppressor cells (PPSC) in drug induced hepatitis.¹⁷ Table 2 shows the clinical manifestations and alterations in liver tests observed in the patients studied. Jaundice was present in 69 (73%) patients and extrahepatic manifestations such as fever, rash, and eosino-

TABLE 2 Clinical manifestations and alterations in liver function tests observed in patients with drug induced liver injury

Variable	Number (%)
<i>Clinical manifestations</i>	
Jaundice	69 (73)
Fever	37 (39)
Asthenia	36 (38)
Rash	28 (29)
Abdominal pain	20 (21)
Nausea/vomiting	18 (19)
Anorexia	10 (11)
Arthralgia	5 (5)
Adenomegaly	5 (5)
Myalgia	4 (4)
Other	10 (11)
No symptoms	10 (11)
<i>Alterations in liver tests</i>	
Bilirubin	
Slight*	47 (49)
Moderate†	22 (23)
Severe‡	26 (27)
Alkaline phosphatase	
Slight*	35 (37)
Moderate†	43 (45)
Severe‡	17 (18)
γ-Glutamyltranspeptidase	
Slight*	28 (29)
Moderate†	33 (35)
Severe‡	34 (36)
Alanine aminotransferase	
Slight*	41 (43)
Moderate†	30 (32)
Severe‡	24 (25)
Aspartate aminotransferase	
Slight*	32 (34)
Moderate†	30 (32)
Severe‡	33 (35)

*Bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <6× the upper limit of normal, alkaline phosphatase (AP) <3× and γ-glutamyltranspeptidase (GGT) <4×.

†Bilirubin, ALT and AST 6–15×, AP 3–6×, GGT 4–10×.

‡Bilirubin, ALT and AST >15×, AP >6×, GGT >10×.

TABLE 3 Characteristics of the controls studied

	Patients with liver disease	Patients with exposure to drugs*	Healthy controls
No. of cases	15	35	106
Age (mean (SD))	48.4 (6.8)	43.5 (3.8)	38.9 (2.3)
Sex (M/F)	9/6	10/25	41/65
Disease		NA	NA
Hepatitis C	4		
Alcoholic liver disease	4		
Cholangitis†	2		
PBC	2		
Acute hepatitis B	2		
Wilson's disease	1		

*Patients recently exposed to drugs but without adverse effects;

†Cholangitis associated with gallstones; PBC, primary biliary cirrhosis.

philia were observed in 37, 28, and 33 patients respectively. The clinicolaboratory pattern observed in these patients was classified as cholestatic in 37, hepatocellular in 39, and mixed in 19, according to criteria by Danan.²⁰ The diagnosis of drug induced liver injury was based on the establishment of a consistent temporal relation between drug intake and the onset of clinical symptoms and on the exclusion of alternative causes of liver injury—viral hepatitis, alcoholic liver disease, biliary tree obstruction, and pre-existing liver disease by standard criteria.² Procedures used to rule out alternative causes included abdominal ecography in 88 (93%) patients, liver biopsy in 48 (51%), and endoscopic retrograde cholangiopancreatography in 20 (21%). Five patients were subsequently and inadvertently reexposed to the suspected drugs. The clinical symptoms reappeared in all of these patients. A diabetic, 22 year old man was accidentally reexposed three times to cotrimoxazole, with subsequent increases in liver enzyme concentrations.

Three types of controls—healthy controls (n=106), individuals with recent exposure to the same drugs but without adverse effects (n=35), and patients with liver diseases unrelated to drugs (n=15), were also studied (table 3).

PREPARATION OF DRUG SOLUTIONS

The drugs selected for study in each case were those with a significant probability of being involved in the liver lesion on the basis of the

TABLE 4 Drugs tested in controls with recent exposure to the suspected drugs without adverse effects

Drugs tested	Number of cases
Cotrimoxazole	6
Erythromycin	5
Flucloxacillin	3
Amoxycillin and clavulanic acid	2
Griseofulvin	2
Nimesulide	2
Allopurinol	2
Phenytoin	1
Nitrofurantoin	1
Ampicillin	1
Ketoconazole	1
Enalapril	1
Captopril	1
Amoxycillin	1
Sulpiride	1
Glibenclamide	1
Fentiazac	1
Pyritinol	1
Amineptine	1

Figure 1: Lymphocyte stimulation indexes in patients and controls (A) in the presence of the suspected drug and (B) in the presence of the suspected drug and a prostaglandin inhibitor. The numbers in brackets represent the stimulation indexes of cases that fall outside the scale. The horizontal line represents the level of stimulation index above which results are considered positive.

usual clinical criteria, with emphasis on the temporal relation between drug intake and adverse effect. Table 4 lists drugs tested in control subjects who had taken the drugs without developing adverse effects.

Drugs were dissolved in RPMI medium (Gibco) and left in a magnetic shaker for six hours. Drugs insoluble in aqueous medium were dissolved in 95% ethyl alcohol and diluted in RPMI medium, with a final concentration of alcohol below 0.002% which is known to be non-toxic to the cultures.²¹ Drug solutions were then ultrasonicated at 50 Hz for one minute and passed through a 0.22 μ m millipore filter. Five dilutions of the drugs in RPMI were prepared, so that the median concentration corresponded to the mean plasma concentration observed in humans after the ingestion of a therapeutic dose of the drug; two concentrations above and two below were also used.

LYMPHOCYTE PROLIFERATION IN DRUG SOLUTIONS

Lymphocyte proliferation studies were performed as described previously.²² Briefly, peripheral blood mononuclear cells (PBMC) were isolated from heparinised venous blood, washed three times in phosphate buffered saline (PBS), and resuspended at a concentration of 1×10^6 /ml in RPMI 1640 medium (Gibco) enriched with 15% inactivated fetal calf serum (FCS), 2 mM L-glutamine (Gibco), and 2% penicillin (100 U/ml)/streptomycin (100 μ g/ml). In patients 57–95, 10% human AB serum (Sigma) was used instead of FCS, and penicillin/streptomycin was substituted

with 20 μ g/ml gentamicin (Sigma). PBMC (100 μ l) were distributed to each well of a 96 well microtitre plate (Costar) and 20 μ l of each drug concentration was added to the wells. Experiments were done in triplicate. Cells were cultured for six days at 37°C in a humidified, 5% CO₂ enriched atmosphere; 12 hours before the end of the cultures 1 μ Ci ³H-thymidine (specific activity 23 Ci/mmol, Radiochemical Centre, Amersham, UK) was added to the cultures. Cells were harvested on filter discs and counted in a β -counter. Results were expressed as counts per minute (cpm) and as stimulation indexes (SI = cpm of cultures with drug/cpm of cultures without drug). Results were considered positive when SI was higher than 2.

LYMPHOCYTE PROLIFERATION IN THE PRESENCE OF A PROSTAGLANDIN INHIBITOR

A modification to the lymphocyte proliferative assay, consisting of the addition of a prostaglandin inhibitor (PI; indomethacin 1 μ g/ml) to the cultures stimulated with drugs was simultaneously applied to patients and controls. The rationale for this approach has been published elsewhere.¹⁷ Activated monocytes in cultures of PBMC can secrete prostaglandins, namely PGE₂, that inhibit the lymphocyte proliferative responses to various antigens *in vitro*.^{23, 24} Several studies have shown that it is possible to restore the proliferative response by adding prostaglandin inhibitors to the cultures.^{25, 26}

Results were expressed as cpm and SI (SI = cpm of cultures with drug and PI/cpm of cultures with drug and without PI).

TABLE 5 Drugs to which specific T cell reactivity was detected

Drug	Number of cases
Antimicrobials (n=13)	
Cotrimoxazole	6
Erythromycin	1
Flucloxacillin	1
Ampicillin	1
Amoxycillin	1
Ketoconazole	1
Griseofulvin	1
Isoniazid	1
Antirheumatics/analgesics (n=10)	
Allopurinol	3
Fentiazac	2
Pyrazinobutazone	1
Ibuprofen	1
Oxaprozin	1
Salazosulphapyridine	1
Paracetamol	1
Antihypertensives (n=10)	
Captopril	4
α -Methyldopa	2
Enalapril	1
Nebivolol	1
Chlorothiazide	1
Nifedipine	1
Psychotropics (n=6)	
Amineptine	2
Dothiepin	2
Chlorpromazine	1
Sulpiride	1
Anticonvulsants (n=5)	
Phenytoin	3
Carbamazepine	2
Hormones/nutrition (n=3)	
Glibenclamide	1
Tamoxifen	1
Levonorgestel and ethinylestradiol	1
Other/mixed (n=6)	
Pyritinol	4
Lovastatin	1
Propylthiouracil	1

MITOGEN INDUCED LYMPHOCYTE PROLIFERATION Responses to mitogens (phytohaemagglutinin (PHA) 10 μ g/ml and pokeweed mitogen (PWM) 2.5 μ g/ml) were performed in patients and controls in order to assess the adequacy of the culture system.²⁷

EVIDENCE FOR PPSC IN VITRO AND CLINICAL CHARACTERISTICS

The possible associations between the presence of PPSC in vitro and the clinical characteristics of patients were analysed. These included age, sex, clinicolaboratory characteristics, presence of eosinophilia, pharmacological groups, latency time, remission time, and severity of the hepatitis as assessed by the maximal concentration of bilirubin, alkaline phosphatase, γ -glutamyltranspeptidase, and aminotransferases.

STATISTICAL ANALYSIS

The unpaired *t* test was used to assess statistical significance of differences observed in the means of continuous variables. The χ^2 test and Fisher's exact test were used to compare dichotomous variables. For non-parametric variables the Mann-Whitney U test was used. Statistical significance was considered at a *p* value of 0.05.

Results

Analysis of lymphocyte proliferative responses to PHA and PWM did not show any significant differences between patients and controls,

indicating that non-specific T cell mediated immune responses were not affected in patients (data not shown).

Figure 1 shows the stimulation indexes of lymphocyte proliferative responses to drugs in patients and controls. For each patient, the stimulation index represented corresponds to the higher lymphocyte response observed in the five different concentrations of the drug tested. Part A of the figure shows the stimulation indexes observed in standard conditions—that is, lymphocyte cultures with drugs alone. Significant proliferative responses to drugs (SI>2) were seen in 25 (26%) patients with a clinical diagnosis of drug induced liver injury. In these positive cases, stimulation indexes ranged from 2.1 to 41.2. The four cases with higher stimulation indexes correspond to cases of pyritinol induced prolonged cholestatic hepatitis. It is worth noting that no significant reactivity was found in the three types of controls studied. Part B of the figure shows the stimulation indexes observed when a prostaglandin inhibitor was added to the lymphocyte cultures. Positive results (SI>2) were observed in 53 (56%) patients with a clinical diagnosis of drug induced liver injury. Thus, a significant number of positive cases (n=28) was found only after use of this method. In most cases, an increase in the stimulation indexes was observed when a prostaglandin inhibitor was added to the cultures, even in cases already positive in standard conditions. A notable exception to this phenomenon was observed in the group of non-steroidal anti-inflammatory drugs (NSAIDs).

Table 5 lists the drugs to which specific T cell reactivity was detected. The total number of drugs studied was 152, corresponding to a mean of 1.6 drugs per patient, with limits between 1 and 6. In all cases there was agreement between the drugs identified by immunological studies and the drugs suspected after a standard clinical imputation process was applied.²⁸ In cases in which two or more drugs were equally suspected by clinical assessment, lymphocyte reactivity was found to one drug only. In three cases of cotrimoxazole induced hepatitis, lymphocyte reactivity was tested both to sulphamethoxazole and trimethoprim, and in all cases reactivity was observed only to sulphamethoxazole. In another case of erythromycin induced cholestatic hepatitis, in which the patient had been exposed successively to different salts of erythromycin, lymphocyte reactivity was tested against ethylsuccinate, estolate, and lactobionate, as well as to base erythromycin; lymphocyte sensitisation was detected only to lactobionate.

In five cases, lymphocyte proliferative responses to the suspected drug were detected on two different occasions (table 6). In three cases the reactivity decreased and in two no changes were observed.

Table 7 presents the possible associations between the presence of PPSC in vitro and the clinical characteristics of patients. Statistically significant differences were found between cases with and without evidence of PPSC when

TABLE 6 Cases of drug induced liver injury studied on two different occasions

Case no.	Clinicopathological pattern	Suspected drug	First study		Second study	
			Time of study*	Maximal SI observed	Time of study*	Maximal SI observed
1	Mixed	Erythromycin	2 months	3.9	6 months	1.3
2	Hepatocellular	Cotrimoxazole	2 months	4.1	4 months	3.2
3	Cholestatic	Pyritinol	9 months	44.5	10 months	45.2
4	Cholestatic	Flucloxacillin	3 months	3.2	6 months	3.1
5	Hepatocellular	Phenytoin	2 months	2.8	4 months	2.2

*Time between onset of symptoms and the study.

considering duration of latency ($p=0.014$) and remission ($p=0.013$), severity of hepatitis as assessed by alanine aminotransferase ($p=0.027$) and aspartate aminotransferase ($p=0.012$) concentrations, and the pharmacological groups of the drugs inducing hepatitis ($p=0.017$).

Cases with evidence of PPSC had a significantly lower median latency period (11 days) than cases without PPSC (15 days) as assessed by the Mann-Whitney U test ($p=0.042$). The median duration of remission was also lower in the first group (43 v 65 days) although this did not reach statistical significance ($p=0.146$).

Table 8 shows the global results of specific T cell reactivity to drugs tested in 95 patients with a clinical diagnosis of drug induced liver injury, using different methods. It is worth noting that the addition of a prostaglandin inhibitor to the lymphocyte cultures increased significantly the ability to detect lymphocyte reactivity to drugs. The results obtained in a series of 25 cases previously published¹⁸ in which ex vivo drug antigens were used instead of the parental drug are also shown in table 8

TABLE 8 Comparison of results observed in lymphocyte stimulation tests (LST) with drugs (standard), with drugs and a prostaglandin inhibitor (PI), and with ex vivo drug antigens (EVDA)

Test	Cases tested (n)	Positive cases (n (%))
Standard LST	95	25 (26)
LST + PI	95	53 (56)
LST + EVDA*	25	7 (28)
LST + PI + EVDA	25	22 (88)†
Total	95	62 (65)†

*Data relating to these 25 patients have been published previously.¹⁸

†Cases positive in at least one of the three methods.

for comparison. Although the percentage of positive cases with this approach was only 28%, several of these cases were not detected when the test was done in standard conditions or with simple addition of a prostaglandin inhibitor. Finally, in cases where the three different approaches were simultaneously applied—that is, lymphocyte proliferation to drugs alone, lymphocyte proliferation to drugs in the presence of a prostaglandin inhibitor, and lymphocyte proliferation to ex vivo drug antigens, a much higher percentage of positive cases was observed (88%).

In order to assess whether a positive in vitro test was associated with the presence of extrahepatic manifestations which are usually considered to be a clinical marker of an immunological mechanism for drug hepatotoxicity, we analysed the frequency of these extrahepatic manifestations in patients with positive and negative test results. No significant differences were found, as assessed by Fisher's exact test.

Discussion

Specific T cell reactivity to drugs has been used in an attempt to improve diagnosis of drug induced liver injury but a low sensitivity of the test has been reported.^{14 15} Most studies investigated individual cases or small series. We have analysed the value of this method in a large series of well characterised patients, subject to long follow up periods. We used modifications to the standard tests, in an attempt to overcome some of the problems that could theoretically explain the low sensitivity of the test—namely, the presence of prostaglandin producing suppressor cells in the in vitro culture system.^{17 23 29}

Our results showed that this modification increased significantly the sensitivity of the test, without decreasing its specificity. In fact, no reactivity was found in any of the three types of controls studied. Control subjects with recent exposure to the suspected drugs without adverse effects are particularly important in this kind of study, because sensitisation to the

TABLE 7 Clinical and laboratory features and their relation to the presence or absence of prostaglandin producing suppressor cells (PPSC) in vitro

Independent variable	Evidence of PPSC	No evidence of PPSC	Statistical significance
Age (mean (SD))	42.9 (18.0)	47.8 (18.2)	$p>0.05^*$
Sex (M/F)	20/24	20/31	$p=0.684^†$
Bilirubin			
$\geq 10\times$	15	20	
$<10\times$	29	31	$p=0.761^†$
AP			
$\geq 5\times$	29	21	
$<5\times$	13	30	$p=0.525^†$
GGT			
$\geq 8\times$	22	24	
$<8\times$	22	27	$p=0.936^†$
ALT			
$\geq 10\times$	15	30	
$<10\times$	29	21	$p=0.027^†$
AST			
$\geq 10\times$	19	36	
$<10\times$	25	15	$p=0.012^†$
Eosinophilia (Y/N)	18/26	15/36	$p=0.338^†$
Latency time			
≤ 10 days	19	10	
>10 days	22	40	$p=0.014^†$
Remission time			
≤ 60 days	29	21	
>60 days	13	30	$p=0.013^†$
Pattern			
Cholestatic	16	21	
Hepatocellular	20	19	$p=0.717^‡$
Mixed	8	11	
Pharmacological group			
Antimicrobial	13	12	
NSAID/analgesic	3	16	
Psychotropic	5	11	$p=0.017^‡$
Antihypertensive	10	1	
Other	13	11	

*Student's t test; †two tail Fisher's exact test; ‡ χ^2 test; AP, alkaline phosphatase; GGT, γ -glutamyltranspeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NSAID, non-steroidal anti-inflammatory drug.

Laboratory values are expressed in multiples of the upper limits of normal.

drug could be an epiphenomenon observed in those exposed to the drug and unrelated to the hepatic lesion. Conversely, some liver diseases could somehow alter the immune system and predispose to non-specific sensitisation to drugs. Negative results observed in our controls with liver diseases unrelated to drugs exclude this possibility.

The use of a large number of concentrations of the drug seems to be of considerable importance, because in several cases lymphocyte reactivity was detected only to one or two concentrations of the drug. This finding is not totally unexpected as the optimal concentration of the drug for generating the adequate antigenic presentation *in vitro* is unknown. Furthermore, it is worth noting that the optimal concentration of a certain drug varies from one person to another. Therefore, the criteria of choosing a concentration corresponding to the average plasma therapeutic concentration of the drug and two concentrations above and two below that level are clearly arbitrary, although it was shown to be of practical importance in the sense that an optimal concentration could be either below or above the chosen reference concentration.

As suggested in our early studies,^{16 17} the increase in lymphocyte proliferation in response to drugs by the addition of a prostaglandin inhibitor to the cultures suggests that it is the presence of prostaglandin producing suppressor cells that prevents lymphocyte sensitisation to drugs being detected in standard conditions. This *in vitro* phenomenon seems to be clinically relevant *in vivo*, in the sense that patients in which this phenomenon was detected had a less severe disease, as assessed by aminotransferase concentrations and more rapid cure. This observation is interesting in view of the data showing a protective role of prostaglandins, namely PGE₂, in experimental models of liver injury,³⁰ as well as in patients with fulminant hepatic failure.³¹ Recent studies have shown that PGE₂ profoundly inhibits the synthesis of interleukin 2 and interferon γ ,^{32 33} two lymphokines associated with the Th1 pattern, but not of interleukin 4 and interleukin 10 secreted by Th2 cells. There is growing evidence that the Th1 subset may be involved in organ specific autoimmune diseases, not only in animal models,³⁴ but also in humans, as is the case in multiple sclerosis³⁵ and rheumatoid arthritis.³⁶ Many cases of drug induced prolonged cholestasis associated with the vanishing bile duct syndrome show some features in common with autoimmune liver diseases, such as primary biliary cirrhosis (PBC).^{37 38} It has been shown that biliary epithelial cells from patients with PBC exhibit aberrant expression of HLA class II antigens³⁹ in association with T cell autoreactivity against biliary autoantigens,⁴⁰ and this abnormal expression could be dependent on interferon γ .^{41 42} Thus, it is tempting to speculate that, by inhibiting interferon γ and favouring a switch from the Th1 to the Th2 subset, PGE₂ may have an important role in preventing drug induced autoimmune liver disease.

An additional factor that could contribute to the high rate of detection of sensitised T cells in our series may be related to the rigorous and strict criteria we used in establishing the diagnosis of drug induced liver injury. Furthermore, we believe that in our series cases of liver damage induced by dose independent idiosyncratic metabolic mechanisms are under-represented.

Antihypertensives and some antimicrobial drugs seem to be more prone to inducing prostaglandin producing suppressor cells than other pharmacological groups. The inability to detect this phenomenon in the NSAID group is probably because these drugs are already prostaglandin inhibitors and therefore no additional effect is obtained with the addition of indomethacin.

We do not question the usual practice of diagnosing drug induced liver injury by clinical criteria, with emphasis on the exclusion of alternative causes and the establishment of a consistent temporal relation between drug intake and the onset of clinical manifestations.² However, in patients exposed to more than one drug and particularly for recently marketed drugs, the demonstration of specific T cell reactivity to a given compound represents additional evidence in favour of its involvement in the induction of liver injury⁶ and is also important for defining the type of mechanism involved.

It is usual clinical practice to assume that the presence of clinical manifestations such as rash, arthralgia, and eosinophilia is the best marker for an immunological mechanism in drug induced hepatotoxicity.⁴ The fact that such clinical markers were absent in about 70% of our patients with a demonstrable T cell reactivity to drugs challenges this view. Furthermore, our results showing lymphocyte sensitisation to drugs in as many as 65% of the patients suggest that immunological mechanisms are much more frequent in drug hepatotoxicity than previously assumed.⁷ However, this does not preclude the possibility of coexistence of metabolic idiosyncratic mechanisms that could be responsible for the formation of reactive metabolites involved in the induction of the abnormal immune response.

Cross reactivity between drugs from the same pharmacological group often occurs and it is normally recommended that a patient with hepatitis associated with a given drug should avoid taking any drug belonging to the same group.⁴³ However, our preliminary results on this topic suggest that drug sensitisation seems to be highly specific. In fact, in several cases in which patients had been exposed to pharmacologically related compounds or even to different salts of a given drug, lymphocyte reactivity was detected only to one drug or to a particular drug salt. Furthermore, in the rare instances (five cases) in which patients had been tested more than once within a period of few weeks after the onset of the clinical symptoms, reactivity was always detected to the same drug. Taken together, these data clearly show the high specificity of these *in vitro* tests.

The notable increase in the sensitivity of drug specific T cell reactivities obtained with this new approach, together with its high specificity, could lead to a recommendation for the more general use of these tests in clinical practice.⁴⁴ The only limitation to such widespread use is that the relative complexity of this method implies that such tests should be confined to specialised laboratories with experience in *in vitro* functional cellular immunology techniques. However, the renewed interest in drug induced liver injury and the importance of more accurate diagnoses probably justifies the effort required of specialised laboratories to make such tests available in the investigation of selected cases of drug induced hepatitis.

In conclusion, modified lymphocyte transformation test used in our study significantly increased our ability to detect lymphocyte sensitisation to drugs without altering the specificity of the test. We therefore suggest that the study of specific T cell reactivity to drugs should have a place in the diagnosis of drug induced liver injury, particularly in patients exposed to more than one drug.

This project was supported in part by grants from JNICT (Junta Nacional de Investigação Científica e Tecnológica, Lisbon, Portugal) to RMMV.

- Zimmerman HJ. Classification of hepatotoxins and mechanisms of toxicity. In: *Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver*. New York: Appleton-Century-Crofts, 1978: 91–121.
- Shearman DJC, Finlayson NDC. Drugs, toxins and the liver. In: *Diseases of the gastrointestinal tract and liver*. London: Churchill Livingstone, 1989: 527–34.
- Stricker BHC. Diagnosis and causality assessment of drug induced hepatic injury. In: Dukes MNG, ed. *Drug-induced hepatic injury*. Amsterdam: Elsevier, 1992: 1–21.
- Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. *Br J Clin Pharmacol* 1992; **34**: 377–95.
- DeLeve LD, Kaplowitz N. Mechanisms of drug induced liver disease. *Gastroenterol Clin North Am* 1995; **4**: 787–810.
- Pohl LR. Drug induced allergic hepatitis. *Semin Liver Dis* 1990; **10**: 305–15.
- Pessayre D. Role of reactive metabolites in drug induced hepatitis. *J Hepatol* 1995; **23**: 16–24.
- Gómez-Lechón MJ, Carrasquer J, Berenguer J, Castell JV. Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug induced hepatitis. *Clin Exp Allergy* 1996; **26**: 590–6.
- Victorino RMM, Maria VAJ, Correia AP, de Moura MC. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. *Arch Intern Med* 1987; **147**: 987–9.
- Maria VAJ, Silva JP, Victorino RMM. Agranulocytosis and liver damage associated to pyrazinobutazone with evidence for an immunological mechanism. *J Rheumatol* 1989; **16**: 1484–5.
- Maria VAJ, Victorino RMM. Hypersensitivity immune reaction as a mechanism of dilevalol associated hepatitis. *Ann Pharmacother* 1992; **26**: 924–6.
- Hofer T, Becker EW, Weigand K, Berg PA. Demonstration of sensitized lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis. *J Hepatol* 1992; **15**: 262–3.
- Tsutsui H, Terano Y, Sakagami C, Hasegawa I, Mizoguchi Y, Morisawa S. Drug specific T cells derived from patients with drug induced allergic hepatitis. *J Immunol* 1992; **149**: 706–16.
- Walton B, Dumonde DQ, Williams C, Jones D, Strunin JM, Layton JM, et al. Lymphocyte transformation. Absence of increased responses in alleged halothane jaundice. *JAMA* 1973; **225**: 494–8.
- Rotmensch HH, Leiser A, Dan M, Klyman A, Livini E, Ilie B, et al. Evaluation of prajmalium-induced cholestasis by immunological tests. *Arch Intern Med* 1981; **141**: 1797–801.
- Victorino RMM, Maria VAJ. Drug induced hepatitis and lymphocyte transformation test in presence of prostaglandin inhibitor. *Lancet* 1986; **i**: 1209–10.
- Victorino RMM, Maria VAJ, Pinto L. Evidence for prostaglandin producing suppressor cells in drug induced hepatitis and implications in the diagnosis of drug sensitization. *Clin Exp Immunol* 1992; **87**: 132–7.
- Maria VAJ, Pinto L, Victorino RMM. Lymphocyte reactivity to ex-vivo drug antigens in drug induced hepatitis. *J Hepatol* 1994; **21**: 151–8.
- Benichou C. Criteria of drug induced liver disorders: report of an international consensus meeting. *J Hepatol* 1990; **11**: 272–6.
- Danan G. Consensus meeting on causality assessment of drug induced liver injury. *J Hepatol* 1988; **7**: 132–6.
- Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC. Prostaglandin-producing suppressor cells in Hodgkin's disease. *N Engl J Med* 1977; **297**: 963–8.
- Victorino RMM, Maria VAJ. Modifications of the lymphocyte transformation test in a case of drug induced cholestatic hepatitis. *Diagnostic Immunology* 1985; **3**: 171–81.
- Goodwin JS, Webb DR. Regulation of the immune response by prostaglandins. *Clin Immunol Immunopathol* 1980; **15**: 106–22.
- Kelleher D, Murphy A, Feighery C, Weir DG, Keeling PWN. Lymphocyte proliferation in inflammatory bowel disease: effect of monocyte suppressor cell. *Eur J Gastroenterol Hepatol* 1990; **2**: 457–61.
- Victorino RMM. Indomethacin sensitive suppressor cells in Crohn's disease: a possible role in decreased lymphocyte responsiveness. *J Clin Lab Immunol* 1983; **11**: 197–201.
- Foley P, Kazazi F, Biti R, Sorrell TC, Cunningham AL. HIV infection of monocytes inhibits the T-lymphocyte proliferative response to recall antigen, via production of eicosanoids. *Immunology* 1992; **75**: 391–7.
- Maria VAJ, Pinto LA, Victorino RMM. Inhibition of lymphocyte proliferation induced in vitro by microbial antigens in HIV-infected subjects. *J Med Virol* 1991; **35**: 241–5.
- Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. *Hepatology* 1997 (in press).
- De Grujil TD, Moore JJ, De Vries E, von Blomberg-van der Flier BME, Fonk JCM, Scheper RJ. Augmentation of antigenic-specific lymphoproliferative responses in vitro by biological response modifiers. *Clin Exp Immunol* 1994; **96**: 535–40.
- Tsujii H, Okamoto Y, Kikuchi E, Matsumoto M, Nakano H. Prostaglandin E₂ and rat liver regeneration. *Gastroenterology* 1993; **105**: 495–9.
- Cattral MS, Altraif I, Greig PD, Blendis L, Levy GA. Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. *Am J Med* 1994; **97**: 369–73.
- Betz M, Fox BS. Prostaglandin E₂ inhibits production of Th1 lymphokines but not of Th2 lymphokines. *J Immunol* 1991; **146**: 108–13.
- Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. *Immunol Today* 1991; **12**: 349–52.
- Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. *Immunol Today* 1995; **16**: 34–8.
- Brod SA, Benjamin D, Hafner DA. Restricted T cell expression of IL-2/IFN- γ mRNA in human inflammatory disease. *J Immunol* 1991; **147**: 810–5.
- Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. *Proc Natl Acad Sci USA* 1994; **91**: 5862–6.
- Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, Toyota T. A case of drug induced ductopenia resulting in fatal biliary cirrhosis. *Liver* 1993; **13**: 227–31.
- Davies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. *J Hepatol* 1994; **20**: 112–6.
- Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. *Lancet* 1984; **ii**: 1009–13.
- Miyamoto T, Maeda T, Onishi S, Yamamoto Y. T cell auto-reactivity against a 28 kD biliary protein (B1-p28) in primary biliary cirrhosis. *J Hepatol* 1995; **22**: 423–30.
- Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB. Analysis of the effects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. *J Immunol* 1983; **131**: 768–72.
- Freilich BL, Hu KQ, Vierling JM. Immunopathogenesis of autoimmune hepatobiliary diseases. *Curr Opin Gastroenterol* 1994; **10**: 257–68.
- Hagley MT, Benak RL, Hulisz DT. Suspected cross-reactivity of enalapril and captopril-induced hepatotoxicity. *Ann Pharmacother* 1992; **26**: 780–1.
- Berg PA, Becker EW. The lymphocyte transformation test—a debated method for the evaluation of drug allergic hepatic injury. *J Hepatol* 1995; **22**: 115–8.